Scholarly Sources on Survodutide

[keangkong]

Arun, et al. (pre-publication, 2025). Survodutide- A Dual GLP-1 - Glucagon Agonist Reshaping Cardiometabolic Care. Cardiology Rev., https://doi.org/10.1097/crd.0000000000001062.

Awad, et al. (2025). Evaluating the efficacy and safety of survodutide for obesity - a systematic review and meta-analysis of randomized controlled trials. Baylor Univ. Med. Ctr. Proceedings 38(4), 514-522.

Bain & Williams (2024). Glucagon—a new player in weight management therapeutics[Q]. Lancet Diabetes & Endocrinology 12(3), P150-151,

Blüher, et al. (2024). Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon-GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes - a randomised clinical trial. Diabetologia 67, 470–482.

Dutta, et al. (2025). Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication -A Systematic Review and Meta-Analysis. Indian J. Endocrinology & Metabolism 29(3), 253-259.

Ekinci, et al. (2024). Subgroup analysis by gender and body mass index (BMI) in people living with overweight-obesity in the survodutide, a glucagon-GLP-1 receptor dual agonist, phase II trial. Obesity Res. & Clin. Pract. 18(5), S39.

Kaya, et al. (2024). Survodutide in MASH - bridging the gap between hepatic and systemic metabolic dysfunction. Expert Opn Investigational Drugs, 33(12), 1167–1176.

Klein, et al. (2024). Perspectives in weight control in diabetes – Survodutide. Diabetes Res. & Clin. Prac. 207, 110779.

Kosiborod, et al. (2024). Survodutide for the Treatment of Obesity - Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC - Heart Failure 12(12), 2101-2109.

Lawitz, et al. (2024). Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon-glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J. Hepatology, 81, 837-846.

Le Roux, et al. (2024). A Phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight-obesity. Metabolism, 153, 155848.

Le Roux, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity - a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes & Endocrinology 12(3), 162-173, 3, 162-173.

Le Roux, et al. (2024). 6926 Subgroup Analysis by Gender and Body Mass Index (BMI) in People Living With Overweight-Obesity in the Survodutide, a Glucagon/GLP-1 Receptor Dual Agonist, Phase II Trial. J. Endocrine Soc. 8 (Supplement_1).

Le Roux, et al. (2024). Survodutide, a glucagon receptor-GLP-1 receptor (GCGR-GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity - analysis of a placebo-controlled, randomised phase 2 trial. Eur. Heart J. 45(Supplement_1), ehae666-2895.

Long, et al. (2024). Hepatic GCGR is required for the superior weight loss effects of a structurally related analogue of the dual GCGR-LP1R agonist survodutide. Not yet certified by peer review, https://doi.org/10.1101/2024.09.09.611134.

Mikhail (2024). Survodutide, a promising agent with novel mechanism of action for treatment of obesity and type 2 diabetes. J. Endocrinology & Disorders 8(3), 01–04.

Nelson, et al. (2024). Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis - Results from a randomized, double-blind -controlled phase 2 trial. Obesity Res. & Clin. Pract. 18(5), S50.

Noureddin, et al. (2025). OS-098 Direct effects of survodutide on liver endpoints beyond weight loss - insights from a phase 2 trial of the glucagon receptor-glucagon-like peptide-1 receptor dual agonist survodutide in people with metabolic dysfunction-associated steatohepatitis and fibrosis. J. Hepatology 82, S66–S67.

Noureddin, et al. (2025). SAT-445 Sustained improvements in non-invasive biomarkers with the novel glucagon receptor-glucagon-like peptide-1 receptor dual agonist survodutide - longitudinal analysis from a phase 2 trial in people with metabolic dysfunction-associated steatohepatitis and fibrosis. J. Hepatology 82, S636,

Sanyal, et al. (2024). A phase 2 randomized trial of survodutide in MASH and fibrosis. N. Engl. J. Med. 391(4), 311-319. New England Journal of Medicine, 391(4), 311-319.

Sanyal, et al. (2024). O7 Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis - results from a randomised, double-blind, placebo-controlled phase 2 trial. Gut 73, A4.

Schattenberg, et al. (2025). SAT-423 Survodutide, a glucagon/GLP-1 receptor dual agonist, in people with MASH with moderate-to-advanced liver fibrosis (stage F2-F3) - rationale and design of an event-driven, multinational, randomised, placebo-controlled, phase 3 trial (LIVERAGETM). J. Hepatology 82, S629-S630.

Targher, et al. (2025). Recent advances in incretin-based therapy for MASLD - from single to dual or triple incretin receptor agonists. Gut 74, 487-497.

Thomas, et al. (2024). The dual GCGR/GLP‐1R agonist survodutide - Biomarkers and pharmacological profiling for clinical candidate selection. Diabetes Obesity & Metabolism 26(6), 2368–2378.

Vinton, et al. (2025). Survodutide: a novel peptide for treatment of obesity and metabolic diseases. Baylor Univ. Med. Ctr. Proceedings 38(4), 523.

Wan, et al. (2024). Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss - a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome, 16(1), 264.

Wharton, et al. (2024). Survodutide for treatment of obesity - rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE ‐1 and ‐2). Obesity, 33(1), 67–77. https://doi.org/10.1002/oby.24184

Xiao, et al. (pre-publication, 2025). Efficacy and safety of survodutide on glycemic control and weight loss in adults - A systematic review and meta‐analysis. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70105.

Zimmerman, et al. (2022). BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Molec. Metabolism 66, 101633 ["When the potency was assessed in the presence of 100% human and mouse plasma, BI 456906 [survodutide] showed a potency of 1.0 and 1.6 nM for the human GLP-1R and 8.3 and 16 nM for the human GCGR, respectively].

 

[lessthanhalf]

Thanks for putting that together. I have not come across too many examples of compiled clinical studies for any of the available peptides, wish there were more of these based on science rather than opinion or individual experiences.

 

[keangkong]

Thanks for putting that together. I have not come across too many examples of compiled clinical studies for any of the available peptides, wish there were more of these based on science rather than opinion or individual experiences.

I'm glad that you'll use them. I know that most folks, certainly including me, it is hard to read and understand the scientific articles. I'm much better and finding and getting copies, when necessary, of the studies than at being able to interpret them.

It was easier compiling something on survodutide than it would be on some other weight loss drugs because are not as many articles on survodutide.

 

[cldfront]

Would be interested in take-aways. 🙂

 

[keangkong]

Would be interested in take-aways. 🙂

I haven't taken survodutide. I'd be reluctant to take it because it is less well studied than the FDA approved drugs and reta. Also it seems to carry more side effects than the other weight loss drugs. It seems like it will turn out to be reasonably effectively, probably stronger than semaglutide but weaker than retatrutide. Due to its agonism of the glucagon receptor, it will likely be good at getting rid of liver fat and producing positive cardiovascular benefits.